Safety of Inhaled Tobramycin for Pseudomonas Eradication in People With Cystic Fibrosis Less Than 1 Year of Age.

IF 2.7 3区医学 Q1 PEDIATRICS

Pediatric Pulmonology Pub Date : 2025-06-01 DOI:10.1002/ppul.71162

Daniel Riggsbee, Rebecca S Pettit

{"title":"Safety of Inhaled Tobramycin for Pseudomonas Eradication in People With Cystic Fibrosis Less Than 1 Year of Age.","authors":"Daniel Riggsbee, Rebecca S Pettit","doi":"10.1002/ppul.71162","DOIUrl":null,"url":null,"abstract":"Background: Inhaled tobramycin solution is recommended for eradication treatment of Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (PwCF). However, there is limited information on the safety of inhaled tobramycin in PwCF less than 1 year old and no studies primarily analyzing the safety of the 300 mg inhaled solution. The objective of this study was to compare the incidence of adverse drug events (ADE) of inhaled tobramycin in PwCF less than 1 year old to PwCF ages 1 year to 18 years old.Methods: This retrospective analysis evaluated the incidence of inhaled tobramycin ADEs in PwCF ages 14 days to 18 years with CF between January 01, 2008 to January 01, 2022. PwCF less than 1 year of age (infant group) were matched based on genotype in a 1:3 ratio with a PwCF at least a year old to 18 year-old (children group).Results: Forty-eight patients were included (infant group: 12, children group: 36). Median (IQR) age was 0.48 years (0.2-0.7) and 4.7 years (2.3-10) in infant group and children group respectively (p < 0.05). There were 5 (41.7%) ADE in the infant group and 3 (8.3%) in the children group (p = 0.016). When cough was removed there was no significant difference between the two groups [2 (16.7%) vs. 1 (2.7%), p = 0.15]. There was no difference in treatment failure [3 (25%) vs. 7 (19.4%), p = 0.68].Conclusions: This study found a higher incidence of inhaled tobramycin ADE in infants compared to children. These results show a low risk of ADE outside of cough, indicating that inhaled tobramycin may be safely used in this age group.","PeriodicalId":19932,"journal":{"name":"Pediatric Pulmonology","volume":"60 6","pages":"e71162"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ppul.71162","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Inhaled tobramycin solution is recommended for eradication treatment of Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (PwCF). However, there is limited information on the safety of inhaled tobramycin in PwCF less than 1 year old and no studies primarily analyzing the safety of the 300 mg inhaled solution. The objective of this study was to compare the incidence of adverse drug events (ADE) of inhaled tobramycin in PwCF less than 1 year old to PwCF ages 1 year to 18 years old.

Methods: This retrospective analysis evaluated the incidence of inhaled tobramycin ADEs in PwCF ages 14 days to 18 years with CF between January 01, 2008 to January 01, 2022. PwCF less than 1 year of age (infant group) were matched based on genotype in a 1:3 ratio with a PwCF at least a year old to 18 year-old (children group).

Results: Forty-eight patients were included (infant group: 12, children group: 36). Median (IQR) age was 0.48 years (0.2-0.7) and 4.7 years (2.3-10) in infant group and children group respectively (p < 0.05). There were 5 (41.7%) ADE in the infant group and 3 (8.3%) in the children group (p = 0.016). When cough was removed there was no significant difference between the two groups [2 (16.7%) vs. 1 (2.7%), p = 0.15]. There was no difference in treatment failure [3 (25%) vs. 7 (19.4%), p = 0.68].

Conclusions: This study found a higher incidence of inhaled tobramycin ADE in infants compared to children. These results show a low risk of ADE outside of cough, indicating that inhaled tobramycin may be safely used in this age group.

查看原文本刊更多论文

1岁以下囊性纤维化患者吸入妥布霉素根除假单胞菌的安全性

背景：吸入妥布霉素溶液被推荐用于根除囊性纤维化（PwCF）患者的铜绿假单胞菌（PA）感染。然而，关于1岁以下PwCF吸入妥布霉素安全性的信息有限，也没有研究主要分析300mg吸入溶液的安全性。本研究的目的是比较1岁以下的PwCF与1 ~ 18岁的PwCF中吸入妥布霉素的不良药物事件（ADE）的发生率。方法：回顾性分析2008年1月1日至2022年1月1日期间14天至18岁PwCF患者吸入妥布霉素ade的发生率。1岁以下的PwCF（婴儿组）与1岁至18岁的PwCF（儿童组）按1:3的比例进行基因型匹配。结果：共纳入48例患者（婴儿组12例，儿童组36例）。婴儿组和儿童组的中位（IQR）年龄分别为0.48岁（0.2-0.7岁）和4.7岁（2.3-10岁）(p)。结论：本研究发现婴儿吸入妥布霉素ADE的发生率高于儿童。这些结果表明，咳嗽以外的ADE风险较低，表明吸入妥布霉素可以安全地用于该年龄组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Pulmonology 医学-呼吸系统

CiteScore

6.00

自引率

12.90%

发文量

468

审稿时长

3-8 weeks

期刊介绍： Pediatric Pulmonology (PPUL) is the foremost global journal studying the respiratory system in disease and in health as it develops from intrauterine life though adolescence to adulthood. Combining explicit and informative analysis of clinical as well as basic scientific research, PPUL provides a look at the many facets of respiratory system disorders in infants and children, ranging from pathological anatomy, developmental issues, and pathophysiology to infectious disease, asthma, cystic fibrosis, and airborne toxins. Focused attention is given to the reporting of diagnostic and therapeutic methods for neonates, preschool children, and adolescents, the enduring effects of childhood respiratory diseases, and newly described infectious diseases. PPUL concentrates on subject matters of crucial interest to specialists preparing for the Pediatric Subspecialty Examinations in the United States and other countries. With its attentive coverage and extensive clinical data, this journal is a principle source for pediatricians in practice and in training and a must have for all pediatric pulmonologists.